| | | | | | | | | | |
|
|
|
|
| Dockets Entered
On August 29, 2007
|
|
|
|
|
|
|
|
|
|
|
| Docket #
|
| Title
|
|
|
|
|
|
|
| 1978N-0038
|
| Sunscreen Drug Products
|
|
|
|
|
| 1998D-0077
|
| Treatment of osteoarthritis/drugs, devices and biological pt
|
|
|
|
|
| 2006D-0347
|
| Guidance for Industry, Clinical Laboratories, and FDA Staff on In Vitro Diagnostic Multivariate Index Assays
|
|
|
|
|
| 2006N-0067
|
| Index of Legally Marketed Unapproved New Animal Drugs for Minor Species
|
|
|
|
|
| 2006N-0420
|
| Agency Information Collection Activities; Proposed Collection; Comment Request; Orphan Drugs
|
|
|
|
|
| 2006N-0454
|
| Use of Ozone-Depleting Substances; Removal of Essential-Use Designations
|
|
|
|
|
| 2006P-0307
|
| To amend 21CFR 201.17 regarding expiration dates
|
|
|
|
|
| 2006P-0390
|
| Order the Church of Scientology to clearly disclose the potential health hazards inherent in the use of the E-meter and Scientology's practice of "auditing"
|
|
|
|
|
| 2006P-0394
|
| Revise the labeling requirements for eggs sold in the United States
|
|
|
|
|
| 2006P-0496
|
| Determine whether Sulfamethoxazole, Trimethoprim, and Phenazopyride HCI, have been voluntarily withdrawn or withheld for safety or efficacy reasons
|
|
|
|
|
| 2006P-0505
|
| ANDA for Ursodial Capsules USP, 100 mg 200 mg, and 400 mg
|
|
|
|
|
| 2007D-0125
|
| Guidance for Industry: Evidence-Based Review System for the Scientific Evaluation of Health Claims
|
|
|
|
|
| 2007D-0213
|
| Guidance for Industry on Providing Regulatory Submissions in Electronic Format Receipt Date
|
|
|
|
|
| 2007D-0310
|
| Companion to Guidance for Industry on Pharmacogenomic Data
|
|
| |
|
| 1978N-0038
|
| Sunscreen Drug Products
| |
|
|
|
| EC 1918
|
| Mr. Danny Parris
|
| Vol #:
|
| 160
|
|
|
|
|
| EC 1919
|
| Ms. janet young
|
| Vol #:
|
| 160
|
|
|
|
|
| EC 1920
|
| Ms. Heather Stanley
|
| Vol #:
|
| 160
|
|
|
|
|
| EC 1921
|
| Mrs. Pamela Schmidt
|
| Vol #:
|
| 160
|
|
|
|
|
| EC 1922
|
| Ms. Melissa Forbes
|
| Vol #:
|
| 160
|
|
|
|
|
| EC 1923
|
| Mr. Robert Heilman
|
| Vol #:
|
| 160
|
|
|
|
|
| EC 1924
|
| Mrs. Erin Scharer
|
| Vol #:
|
| 160
|
|
|
|
|
| EC 1925
|
| Ms. Jennifer Wiley
|
| Vol #:
|
| 160
|
|
|
|
|
| EC 1926
|
| Mrs. Jaclyn Hubbart
|
| Vol #:
|
| 160
|
|
|
|
|
| EC 1927
|
| Mr. Benoni Outerbridge
|
| Vol #:
|
| 160
|
|
|
|
|
| EC 1928
|
| Ms. Molli Hoos
|
| Vol #:
|
| 160
|
|
|
|
|
| EC 1929
|
| Ms. Tamera Standage
|
| Vol #:
|
| 160
|
|
|
|
|
| EC 1930
|
| public administration
|
| Vol #:
|
| 160
|
|
|
|
|
| EC 1931
|
| Mrs. Lisa Carroll
|
| Vol #:
|
| 160
|
|
|
|
|
| EC 1932
|
| Ms. Liz Sigel
|
| Vol #:
|
| 160
|
|
|
|
|
| EC 1933
|
| Ms. Julianne Bryant
|
| Vol #:
|
| 160
|
|
|
|
|
| EC 1934
|
| Ms. Brenda Songy
|
| Vol #:
|
| 160
|
|
|
|
|
| EC 1935
|
| Dr. Allison Dixon
|
| Vol #:
|
| 160
|
|
|
|
|
| EC 1936
|
| Dr. Stephenie Riley
|
| Vol #:
|
| 160
|
|
|
|
|
| EC 1937
|
| Ms. Brenna Norton
|
| Vol #:
|
| 160
|
|
| | | | | | | | |
|
| |
|
| EC 2160
|
| Mrs. Kelly Blum
|
| Vol #:
|
| 160
|
|
|
|
|
| EC 2161
|
| Mrs. Molly Mac Ban
|
| Vol #:
|
| 160
|
|
|
|
|
| EC 2162
|
| Senior Services
|
| Vol #:
|
| 160
|
|
|
|
|
| EC 2163
|
| Miss. Phyllis Marino
|
| Vol #:
|
| 160
|
|
|
|
|
| 1998D-0077
|
| Treatment of osteoarthritis/drugs, devices and biological pt
|
|
|
|
|
| LET 1
|
| Osteoarthritis Reseach Society International (OARS
|
| Vol #:
|
| 1
|
|
|
|
|
| 2006D-0347
|
| Guidance for Industry, Clinical Laboratories, and FDA Staff on In Vitro Diagnostic Multivariate Index Assays
|
|
|
|
|
| C 21
|
| Washington Legal Foundation
|
| Vol #:
|
| 3
|
|
|
|
|
| C 22
|
| American Society for Clinical Pathology
|
| Vol #:
|
| 3
|
|
|
|
|
| 2006N-0067
|
| Index of Legally Marketed Unapproved New Animal Drugs for Minor Species
|
|
|
|
|
| LET 1
|
| FDA/CVM
|
| Vol #:
|
| 1
|
|
|
|
|
| 2006N-0420
|
| Agency Information Collection Activities; Proposed Collection; Comment Request; Orphan Drugs
|
|
|
|
|
| NAL 1
|
| FDA
|
| Vol #:
|
| 1
|
|
|
|
|
| 2006N-0454
|
| Use of Ozone-Depleting Substances; Removal of Essential-Use Designations
| |
|
|
|
| C 1813
|
| D Peil
|
| Vol #:
|
| 18
|
|
|
|
|
| C 1814
|
| J Link
|
| Vol #:
|
| 18
|
|
|
|
|
| C 1815
|
| B Bouts
|
| Vol #:
|
| 18
|
|
|
|
|
| C 1816
|
| L Price
|
| Vol #:
|
| 18
|
|
|
|
|
| C 1817
|
| P Adams
|
| Vol #:
|
| 18
|
|
|
|
|
| C 1818
|
| V Roten
|
| Vol #:
|
| 18
|
|
|
|
|
| C 1819
|
| D Marten
|
| Vol #:
|
| 18
|
|
|
|
|
| C 1820
|
| C Griffin
|
| Vol #:
|
| 18
|
|
|
|
|
| C 1821
|
| J Chapa
|
| Vol #:
|
| 18
|
|
|
|
|
| C 1822
|
| E Knudsvig
|
| Vol #:
|
| 18
|
|
|
|
|
| C 1823
|
| V Romano
|
| Vol #:
|
| 18
|
|
|
|
|
| C 1824
|
| P Woznik
|
| Vol #:
|
| 18
|
|
|
|
|
| C 1825
|
| D Prentiss
|
| Vol #:
|
| 18
|
|
|
|
|
| C 1826
|
| R Williams
|
| Vol #:
|
| 18
|
|
|
|
|
| C 1827
|
| H Pickens
|
| Vol #:
|
| 18
|
|
|
|
|
| C 1828
|
| P Henschen
|
| Vol #:
|
| 18
|
|
|
|
|
| C 1829
|
| D Story
|
| Vol #:
|
| 18
|
|
|
|
|
| C 1830
|
| M Gauthier
|
| Vol #:
|
| 18
|
|
|
|
|
| C 1831
|
| J Passenheim
|
| Vol #:
|
| 18
|
|
|
|
|
| C 1832
|
| C Reeves
|
| Vol #:
|
| 18
|
|
| | | | | | | | |
|
| |
|
| 2006P-0307
|
| To amend 21CFR 201.17 regarding expiration dates
|
|
|
|
|
| LET 4
|
| Sapna Lohiya
|
| Vol #:
|
| 1
|
|
|
|
|
| 2006P-0390
|
| Order the Church of Scientology to clearly disclose the potential health hazards inherent in the use of the E-meter and Scientology's practice of "auditing"
|
|
|
|
|
| C 2
|
| David Hogg
|
| Vol #:
|
| 1
|
|
| |
|
| 2006P-0394
|
| Revise the labeling requirements for eggs sold in the United States
|
|
|
|
|
| C 139
|
| Samuel L. D.
|
| Vol #:
|
| 7
|
|
|
|
|
| C 140
|
| Karen Reyes
|
| Vol #:
|
| 7
|
|
|
|
|
| 2006P-0496
|
| Determine whether Sulfamethoxazole, Trimethoprim, and Phenazopyride HCI, have been voluntarily withdrawn or withheld for safety or efficacy reasons
|
|
|
|
|
| AMD 1
|
| Vintage Pharmaceuticals, LLC
|
| Vol #:
|
| 1
|
|
|
|
|
| 2006P-0505
|
| ANDA for Ursodial Capsules USP, 100 mg 200 mg, and 400 mg
|
|
|
|
|
| PAV 1
|
| Gary J. Buehler
|
| Vol #:
|
| 1
|
|
|
|
|
| 2007D-0125
|
| Guidance for Industry: Evidence-Based Review System for the Scientific Evaluation of Health Claims
|
|
|
|
|
| C 7
|
| M. Hartsook
|
| Vol #:
|
| 1
|
|
|
|
|
| NCR 1
|
| FDA
|
| Vol #:
|
| 1
|
|
|
|
|
| NCR 2
|
| Number not Used
|
| Vol #:
|
| 1
|
|
| |
|
| 2007D-0213
|
| Guidance for Industry on Providing Regulatory Submissions in Electronic Format Receipt Date
|
|
|
|
|
| C 4
|
| TEVA PHARMACEUTICALS USA
|
| Vol #:
|
| 1
|
|
|
|
|
| 2007D-0310
|
| Companion to Guidance for Industry on Pharmacogenomic Data
|
|
|
|
|
| GDL 1
|
| Guidance
|
| Vol #:
|
| 1
|
|
|
|
|
| NAD 1
|
| FDA
|
| Vol #:
|
| 1
|
|
|
|
|
| NAL 1
|
| FDA
|
| Vol #:
|
| 1
|
|
|
|
|
| SS 1
|
| Number not Used
|
| Vol #:
|
| 1
|
|
